All Oncology News

Gary Gibbon, MD, pulmonologist and allergist, visited Chicago for a first-of-its-kind transplant procedure, becoming the first person in the U.S. to receive a double-lung and liver transplant for advanced lung cancer.

The PET imaging agent TLX101-CDx has received FDA fast track designation for the characterization of progressive or recurrent glioma.

Durvalumab plus chemotherapy produced superior 3-year survival outcomes vs chemotherapy alone in advanced biliary tract cancer.

Dual HER2-targeted therapy plus checkpoint blockade may offer an effective, tolerable chemotherapy alternative in HER2-positive early breast cancer.

Olutasidenib alone or administered with azacitidine was safe and clinically effective in patients with IDH1-mutated myelodysplastic syndrome.

Simulation-based education can improve health care professionals’ understanding and confidence regarding the treatment of patients with CAR T-cell therapy.

Orca-T demonstrated positive impacts on relapse-free survival and overall survival vs PTCy-based HSCT in acute leukemias and myelodysplastic syndrome.

The regulatory T cell enriched donor cell agent Orca-T was safe and displayed activity in the reduced intensity conditioning setting for patients with advanced hematologic malignancies.

A retrospective cohort study acalabrutinib and zanubrutinib are being increasingly adopted for the treatment of CLL/SLL in the community setting.

Ibrahim Aldoss, MD, discusses the FDA approval of ponatinib plus chemotherapy in newly diagnosed, Ph-positive acute lymphoblastic leukemia.

Nanatinostat plus valganciclovir generated antitumor activity in patients with EBV-positive PTCL in the NAVAL-1 trial.

Glofitamab plus chemotherapy generated an overall survival improvement vs rituximab plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.

The American Nurses Credentialing Center has awarded Magnet® status to Dana-Farber Cancer Institute for the 5th time in a row.

Christian Marth, MD, PhD, discusses outcomes for key subgroups treated with first-line pembrolizumab and lenvatinib in advanced or recurrent endometrial cancer.

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, shares post-progression and updated survival outcomes with frontline rucaparib maintenance in ovarian cancer.

In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.

A real-world study showed zanubrutinib was linked with fewer cardiac adverse effects vs ibrutinib and acalabrutinib in chronic lymphocytic leukemia.

The FDA’s ODAC voted that data support the use of minimal residual disease as an end point to support accelerated approval of treatments in multiple myeloma.

Shirish M, Gadgeel, MD, highlights key treatment advances achieved with antibody-drug conjugates in non–small cell lung cancer.

Anne Favret, MD discusses the evolution of treatment with endocrine-based combination therapies in HR-positive/HER2-negative metastatic breast cancer.

Fox Chase Cancer Center has been recognized by the QOPI Certification Program LLC as successfully completing a 3-year recertification for outpatient hematology-oncology practices that meet nationally recognized standards for quality cancer care.

Updated phase 1 findings with botensilimab/balstilimab in MSS/pMMR mCRC show that the regimen elicited respective 12- and 18-month OS rates of 71% and 62%.

The FDA has received a type C meeting request from Oncolytics Biotech to discuss a registration-enabling trial for pelareorep in HR+/HER2– breast cancer.

Randomized trials are widely recognized to play a pivotal role in the decision-making associated with the establishment of clinical guidelines.

The intravesical gene therapy elicited durable remissions in a high percentage of patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer.

The National Institute for Health and Care Excellence has recommended the use of tisagenlecleucel in pediatric B-cell acute lymphoblastic leukemia.

Experts discuss when to use the PD-1 inhibitor cemiplimab vs the hedgehog inhibitor vismodegib as neoadjuvant treatment in non-melanoma skin cancers.

Experts from across the oncology field highlight their biggest takeaways and the hottest topics from the 2024 AACR Annual Meeting.

Add-on parsaclisib with ruxolitinib resulted in decreased spleen volume and improved symptom assessment scores in patients with myelofibrosis.

The Gulf South Clinical Trials Network has been named a spoke in the ARPA-H Customer Experience Hub, one of 3 regional hubs that comprise ARPANET-H.